Tetra Bio Pharma Inc
F:JAM1

Watchlist Manager
Tetra Bio Pharma Inc Logo
Tetra Bio Pharma Inc
F:JAM1
Watchlist
Price: 0.076 EUR -5%
Market Cap: €104.1m

Relative Value

JAM1 price has not been updated for more than 6 years. This may indicate that the stock has been delisted.
JAM1 doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of JAM1.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JAM1 Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

JAM1 Competitors Multiples
Tetra Bio Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Tetra Bio Pharma Inc
F:JAM1
10.6m EUR 0 -0.3 -0.9 -0.9
US
Eli Lilly and Co
NYSE:LLY
992.9B USD 16.7 53.9 36.2 38.8
US
Johnson & Johnson
NYSE:JNJ
541.8B USD 5.8 20.2 14.1 17.3
CH
Roche Holding AG
SIX:ROG
271.7B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
212.2B GBP 4.9 30.4 19.8 29
CH
Novartis AG
SIX:NOVN
220.1B CHF 4.9 19.3 15.5 20
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.5 11.4 13.3
US
Merck & Co Inc
NYSE:MRK
269.1B USD 4.2 14.1 10 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
151B USD 2.4 15.4 7.7 10.6
FR
Sanofi SA
PAR:SAN
95.6B EUR 1.4 6.9 6.3 6.3
P/S Multiple
Revenue Growth P/S to Growth
CA
Tetra Bio Pharma Inc
F:JAM1
Average P/S: 14.4
Not Available
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
16.7
27%
0.6
US
Johnson & Johnson
NYSE:JNJ
5.8
6%
1
CH
Roche Holding AG
SIX:ROG
4.4
3%
1.5
UK
AstraZeneca PLC
LSE:AZN
4.9
8%
0.6
CH
Novartis AG
SIX:NOVN
4.9
5%
1
DK
Novo Nordisk A/S
CSE:NOVO B
5.4
5%
1.1
US
Merck & Co Inc
NYSE:MRK
4.2
4%
1
IE
E
Endo International PLC
LSE:0Y5F
94
N/A N/A
US
Pfizer Inc
NYSE:PFE
2.4
-2%
N/A
FR
Sanofi SA
PAR:SAN
1.4
5%
0.3
P/E Multiple
Earnings Growth PEG
CA
Tetra Bio Pharma Inc
F:JAM1
Average P/E: 22.8
Negative Multiple: -0.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.9
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.2
6%
3.4
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.4
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.5
2%
8.2
US
Merck & Co Inc
NYSE:MRK
14.1
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.4
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Tetra Bio Pharma Inc
F:JAM1
Average EV/EBITDA: 47.8
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.2
34%
1.1
US
Johnson & Johnson
NYSE:JNJ
14.1
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
19.8
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
US
Merck & Co Inc
NYSE:MRK
10
6%
1.7
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.7
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Tetra Bio Pharma Inc
F:JAM1
Average EV/EBIT: 102.6
Negative Multiple: -0.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.8
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.3
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
29
23%
1.3
CH
Novartis AG
SIX:NOVN
20
12%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.9
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4